We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+30%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.29B
AUM Growth
+$370M
Cap. Flow
+$32.1M
Cap. Flow %
2.48%
Top 10 Hldgs %
19.69%
Holding
198
New
29
Increased
74
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$20.7M
2
AVTR icon
Avantor
AVTR
+$14.9M
3
TGTX icon
TG Therapeutics
TGTX
+$13.5M
4
CELL
PhenomeX Inc. Common Stock
CELL
+$11.4M
5
TXG icon
10x Genomics
TXG
+$10.3M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.9M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.4M
4
PEN icon
Penumbra
PEN
+$10.1M
5
TWST icon
Twist Bioscience
TWST
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.02%
2 Technology 12.16%
3 Consumer Discretionary 8.78%
4 Industrials 6.66%
5 Financials 5.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FFWM
151
DELISTED
First Foundation Inc
FFWM
– –
-140,870
Closed -$1.84M
GPN icon
152
Global Payments
GPN
$22.8B
– –
-3,319
Closed -$589K
HD icon
153
Home Depot
HD
$355B
– –
-5,112
Closed -$1.42M
HPP
154
Hudson Pacific Properties
HPP
$779M
– –
-24,766
Closed -$3.8M
IDXX icon
155
Idexx Laboratories
IDXX
$46.2B
– –
-703
Closed -$276K
LECO icon
156
Lincoln Electric
LECO
$15.4B
– –
-23,029
Closed -$2.12M
LPLA icon
157
LPL Financial
LPLA
$28.6B
– –
-9,271
Closed -$711K
PEN icon
158
Penumbra
PEN
$12.8B
– –
-51,780
Closed -$10.1M
PRLB icon
159
Protolabs
PRLB
$2.13B
– –
-13,418
Closed -$1.74M
RMD icon
160
ResMed
RMD
$30.7B
– –
-1,837
Closed -$315K
SAGE
161
DELISTED
Sage Therapeutics
SAGE
– –
-105,771
Closed -$6.46M
SKYW icon
162
Skywest
SKYW
$4.34B
– –
-83,887
Closed -$2.5M
TXRH icon
163
Texas Roadhouse
TXRH
$13.7B
– –
-40,243
Closed -$2.45M
ZBH icon
164
Zimmer Biomet
ZBH
$18.4B
– –
-1,983
Closed -$262K
SWCH
165
DELISTED
Switch, Inc. Class A Common Stock
SWCH
– –
-197,476
Closed -$3.08M
GBT
166
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-189,392
Closed -$10.4M
MANT
167
DELISTED
Mantech International Corp
MANT
– –
-17,346
Closed -$1.2M
ALXN
168
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-1,974
Closed -$226K
MYOK
169
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-130,321
Closed -$17.8M
LVGO
170
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-34,548
Closed -$4.84M
IMMU
171
DELISTED
Immunomedics Inc
IMMU
– –
-245,698
Closed -$20.9M
DOC
172
DELISTED
PHYSICIANS REALTY TRUST
DOC
– –
-90,035
Closed -$1.61M
3 4 5 6
7

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Nicholas Investment Partners held 198 positions worth $1.29B, up 40% from $925M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Nicholas Investment Partners's Q4 2020 filing shows 29 new, 74 increased, 24 reduced and 25 closed positions. Its largest new stake was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M. The largest sale was Immunomedics Inc, an estimated $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Nicholas Investment Partners's largest Q4 2020 buy was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M.
  • Nicholas Investment Partners added most to TG Therapeutics in Q4 2020, an estimated $13.5M increase.
  • Nicholas Investment Partners's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $10.1M.
  • Nicholas Investment Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $20.9M.
  • Nicholas Investment Partners's ten largest holdings make up 20% of its $1.29B portfolio in Q4 2020.
  • Nicholas Investment Partners opened 29 new positions and closed 25 in Q4 2020.
  • Nicholas Investment Partners's portfolio value rose 40% quarter-over-quarter to $1.29B.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.